10002059 J Clin Psychiatry / Document Archive

Psychiatrist.com Home    Keyword Search

Close [X]

Search Our Sites

Enter search terms below (keywords, titles, authors, or subjects). Then select a category to search and press the Search button. All words are assumed to be required. To search for an exact phrase, put it in quotes. To exclude a term, precede it with a minus sign (-).

Keyword search:

Choose a category:

Choosing the appropriate category will greatly improve your chances of finding the best match.

All files at our sites: J Clin Psychiatry, Primary Care Companion, CME Institute, and MedFair

Search materials from our journals:

Abstracts from The Journal of Clinical Psychiatry, 1996–present, both regular issues and supplements

PDFs of the full text of The Journal of Clinical Psychiatry, 1996–present, both regular issues and supplements (Net Society Platinum [paid subscribers])

PDFs of the full text of The Primary Care Companion to The Journal of Clinical Psychiatry, 1999–present

Search CME offerings:

CME Institute, including CME from journals , supplements, and Web activities for instant CME credit (Net Society Gold [registered users]); also includes information about our CME program

CME activities from regular issues of The Journal of Clinical Psychiatry (Net Society Gold [registered users])

CME Supplements from The Journal of Clinical Psychiatry (Net Society Gold [registered users])


The article you requested is

Need for a New Framework to Understand the Mechanism of All Antipsychotics

J Clin Psychiatry 2000;61:387-388 [letter]
Copyright 2000 Physicians Postgraduate Press, Inc.

To view this item, select one of the options below.

    1. Purchase this PDF for $40
      If you are not a paid subscriber, you may purchase the PDF.
      (You'll need the free Adobe Acrobat Reader.)
    2. Subscribe
      Receive immediate full-text access to JCP. You can subscribe to JCP print + online for $166 individual.
      JCP's 75th AnniversaryCelebrate!
      Celebrate JCP's 75th Anniversary with a special online-only subscription price of $75.
    1. Activate
      If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
    2. Sign in
      As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
  1. Did you forget your password?

Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email


Letter to the Editor

Sir: The advent of atypical neuroleptics has transformed the pharmacologic treatment of schizophrenia. The advent of single photon emission computed tomography (SPECT) and positron emission tomography (PET) neuroreceptor imaging makes it possible to link biochemical events in the human brain to their clinical consequences. Remington and Kapur (supplement 10, 1999) have proposed an interesting model based on studies using PET that takes in account the serotonin-2/dopamine-2 (5-HT2/D2) occupancy threshold: conventional antipsychotics have low 5-HT2/high D2 ratios, olanzapine and risperidone have high 5-HT2/high D2 ratios, clozapine has a high 5-HT2/low D2 ratio, and quetiapine has a low 5-HT2/low D2 ratio. Beyond 80% of D2 blockade, extrapyramidal symptoms appear. To attain optimal blockade, 2 to 4 mg/day of a conventional neuroleptic such as haloperidol is sufficient.